Roche, one of the most powerful pharmaceutical companies in the world, are set to enter the $21 billion per annum diabetes market . The company is understood to be racing to enter the market, after revolutionising the way in which doctors treat cancers .
Roche are stepping up a challenge to diabetic industry leaders Eli Lilly and Novo Nordisk, who are the largest global marketers of insulin . Roche will enter the market with diabetes drugs that make daily injections unnecessary.
Experts forecast that diabetes treatment revenue will soar by over 50 per cent in the next twenty years. Currently, Roche are testing a number of treatments to enter the diabetic market .
Innovative new products, including a peptide-1 analogue that requires just one weekly injection, are expected to be on the market soon.
Roche enters diabetes drug market
Wed, 07 May 2008
Recommended links
Diabetes newsletterDiabetes forum
Diabetes insurance
Global diabetes overview
Further risks from diabetes drug
New herbal diabetic medicine
Drug companies race for share of diabetes market
Diabetes market increasingly competitive
Fake diabetes testing strips on the market
Insulin for diabetics withdrawn from market
New Pfizer insulin inhaler hits the diabetes market
Free diabetes check up at the supermarket
Diabetes drug stays on the market
Lilly plans for Japan diabetes market
